[1]. Tauriello DV, Calon A, Lonardo E, Batlle E. Determinants of metastatic competency in colorectal cancer. Mol Oncol. 2017; 11: 97-119.
[2]. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013; 13:11.
[3]. Reyhani M, Mosadegh F, Nayeri H, Tarkesh N. The relationship between Isoflavone intake from soy consumption and breast Cancer in Isfahan women. Ijbd, 2011; 4: 44-46.
[4]. Lof M, Weiderpass E. Impact of diet on breast cancer risk. Curr Opin Obstet Gynecol. 2009; 21: 80-85.
[5]. mith JE, Rowan NJ, Sullivan R. Medicinal mushrooms: a rapidly developing area of biotechnology for cancer therapy and other bioactivities. Biotechnol Lett. 2002; 24: 1839-1845.
[6]. Ikekawa T. Beneficial effects of edible and medicinal mushrooms on health care. JAIM. 2001; 3: 8 [7]. Mara Kich D, Vincenzi A, Majolo F, Volken de Souza CF, Goettert MI. Probiotic: effectiveness nutrition in cancer treatment and prevention. Nutr Hosp 2016; 33: 1431-1437
[8]. Ali Asgari E, Mirzaie A, Noorbazargan H, Bagheri Kashtali A. Cytotoxicity Effect of Lactobacillus casei Cell Extract as Indigenous Probiotic Bacterium on Colon Cancer Cell Line (HT29) and Analysis of Bax and Bcl2 Apoptosis Gene Expression. Armaghane danesh. 2017; 21: 1192-1206 (Persian)
[9]. Abad CL, Safdar N. The role of lactobacillus probiotics in the treatment or prevention of urogenital infections–a systematic review J. Chemother. 2009; 21: 243-252.
[10]. Ryan RM, Green J, Lewis CE. Use of bacteria in anti‐cancer therapies. Bioessays. 2006; 28: 84-94. [11]. Liu S, Xu X, Zeng X, Li L, Chen Q, Li J. Tumor‑targeting bacterial therapy: A potential treatment for oral cancer. Oncol. Lett. 2014; 8: 2359-2366.
[12]. Yaaghoubi H., Bandepour M.,Kazemi B. Application of bacteria in the treatment of cancer. NCMBJ. 2016; 26: 97100 (Persian)
[13]. Rad AH, Abbasi A, Kafil HS, Ganbarov K. Potential pharmaceutical and food applications of postbiotics: a review. Curr. Pharm. Biotechnol. 2020;21(15):1576-1587.
[14]. Torres JB, Mosley M, Koustoulidou S, Hopkins S, Knapp S, Chaikuad A, Kondoh M, Tachibana K, Kersemans V, Cornelissen B. Radiolabeled cCPE Peptides for SPECT Imaging of Claudin-4 Overexpression in Pancreatic Cancer. J. Nucl. Med. 2020; 61(12):1756-1763.
[15]. Shrestha A, Uzal FA, McClane BA. Enterotoxic clostridia: Clostridium perfringens Enteric Diseases. Microbiol. Spectr. 2018; 6(5): 10./microbiolspec.GPP3-0003-2017.
[16]. Mirzaei S, Batley, J, Ferguson BJ, Gresshoff PM. Transcriptome profiling of the shoot and root tips of S562L, a soybean GmCLVATA1A mutant. Atlas J Biol. 2014;3(1):183-205
[17]. Mirzaei S, Batley, J, EI-Mellouki T, Liu S, Meksem K, Ferguson BJ, Gresshoff PM. Neodiversification of homeologous CLAVATA1-like receptor kinase genes in soybean leads to distinct developmental outcomes. Sci. Rep. 2017; 7:8878, doi: 10.1038/s41598-017-08252-y.
[18]. Abou-Shanab RA, Wongphatcharachai M, Sheaffer CC, Orf JC, Sadowsky MJ. Competition between introduced Bradyrhizobium japonicum strains and indigenous bradyrhizobia in Minnesota organic farming systems. Symbiosis. 2017; 73: 155-163.
[19]. Hwang J-H, Takagi M, Murakami H, Sekido Y, Shin-ya KJCl. Induction of tubulin polymerization and apoptosis in malignant mesothelioma cells by a new compound. JBIR. 23. 2011; 300: 189-96.
[20]. Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011; 30: 87.
[21]. van Puffelen JH, Keating ST, Oosterwijk E, van der Heijden AG, Netea MG, Joosten LA, Vermeulen SH. Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer. Nat. Rev. Urol 2020; 17(9):513-525.
[22]. Enejiyon SO, Adabara NU, Wuna MM, Fasasi RA. Salmonella Typhimurium as a potential anticancer agent: A Review. SLJID. 2020; 10(2):98-113.
[23]. Pyeon D, Vu L, Giacobbi NS, Westrich JA. The antiviral immune forces awaken in the cancer wars. PLoS Pathog. 2020; 16(9):e1008814.
[24]. St Jean AT, Zhang M, Forbes NS. Bacterial therapies: completing the cancer treatment toolbox. Curr Opin Biotechnol 2008; 19(5): 511-517.
[25]. Kaasinen E, Wijkström H, Rintala E, Mestad O, Jahnson S, Malmström PU. Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder. Scand J Urol 2016; 50(5):360-368.
[26]. Kim SJ, You D, Jeong IG, Song C, Hong B, Kim CS, Ahn H, Hong JH. Prognosis of carcinoma in situ according to the presence of papillary bladder tumors after Bacillus Calmette–Guérin immunotherapy. J. Cancer Res. Clin. Oncol. 2019; 145(8):2131-2140.